Expression of KLF4 is a predictive marker for survival in pediatric Burkitt lymphoma.
Krüppel-like factor 4 (KLF4) is expressed in a variety of tissues with diverse physiological functions and activities. KLF4 can also function as a tumor suppressor or an oncogene, depending on the cellular context. Its role in hematological malignancies is controversial. This study examined the expression levels of KLF4 by immunohistochemistry in 73 pediatric non-Hodgkin lymphomas (NHLs) in a tissue microarray and also on several B-NHL cell lines. Elevated levels of KLF4 expression were detected in 66% of lymphoma cases and were more frequent in the Burkitt lymphoma (p = 0.05) subtype. There was a significant predictive power for outcome with low KLF4 expression, predicting a favorable overall survival compared to high levels. Multivariate analyses confirmed the association of KLF4 expression with unfavorable overall survival (p < 0.005). These findings were consistent with analyses in existing NHL microarray datasets. The present findings revealed that KLF4 is overexpressed in Burkitt pediatric lymphoma and is a potential biomarker for inferior overall survival.
Oncology Research Unit, Oncology Hospital, Siglo XXI National Medical Center , IMSS, Mexico City , Mexico.
Alberto
A
Valencia-Hipόlito
Miriam
M
Hernández-Atenógenes
Gabriel G
GG
Vega
Altagracia
A
Maldonado-Valenzuela
Guillermo
G
Ramon
Héctor
H
Mayani
Yolanda
Y
Peña Alonso
Otoniel
O
Martinez-Maza
Alfonso
A
Méndez-Tenorio
Sara
S
Huerta-Yepez
Benjamin
B
Bonavida
Mario I
MI
Vega
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D002051:Burkitt Lymphoma / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality*; D045744:Cell Line, Tumor; D002648:Child; D002675:Child, Preschool; D019295:Computational Biology; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D000090062:Kruppel-Like Factor 4; D051741:Kruppel-Like Transcription Factors / Q000378:metabolism*; D008297:Male; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012307:Risk Factors; D014750:Vincristine / Q000627:therapeutic use
D014408:Biomarkers, Tumor; C000715467:KLF4 protein, human; D000090062:Kruppel-Like Factor 4; D051741:Kruppel-Like Transcription Factors; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
Burkitt; EFS; KLF4; OS; pediatric Burkitt lymphoma